Natera (NTRA) Resumen de Acciones
Natera, Inc. es una empresa de diagnóstico que se dedica al desarrollo y comercialización de servicios de pruebas moleculares en todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
NTRA Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Natera, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$332.03 |
| Máximo en las últimas 52 semanas | US$333.56 |
| Mínimo de 52 semanas | US$157.43 |
| Beta | 1.51 |
| Cambio en 1 mes | 26.73% |
| Variación en 3 meses | 65.26% |
| Cambio de 1 año | 104.36% |
| Variación en 3 años | 498.14% |
| Variación en 5 años | 177.13% |
| Variación desde la OPV | 1,360.11% |
Noticias y actualizaciones recientes
Seeking Alpha • Aug 20
Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per Share
Summary Natera is rated Sell at ~$310, as the stock price bakes in highly optimistic growth and profitability assumptions. Q2 revenue grew 37.7% to $752.8M, driven by oncology test volume and improved reimbursement, but profitability remains elusive. Even with 30% annual revenue growth and 25% operating margins by 2030, fair value is estimated at $255 per share—well below current levels. Exceptional execution and regulatory wins support the business, but current valuation leaves little room for upside or error. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 18
NTRA: Guideline MRD Tailwinds Will Drive Future Oncology Volume Upside
Natera's analyst price target has been raised from $330 to $375, with analysts pointing to stronger modeled revenue growth supported by continued execution in oncology and Women's Health, record and guideline supported Signatera volumes, and updated models after Q2 results that still factor in a higher discount rate and a higher future P/E multiple, alongside somewhat lower projected profit margins. Analyst Commentary Recent Street research around Natera centers on sustained execution in oncology and minimal residual disease, or MRD, testing, with Signatera frequently highlighted as a key driver.Recent updates
Seeking Alpha • Aug 20
Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per Share
Summary Natera is rated Sell at ~$310, as the stock price bakes in highly optimistic growth and profitability assumptions. Q2 revenue grew 37.7% to $752.8M, driven by oncology test volume and improved reimbursement, but profitability remains elusive. Even with 30% annual revenue growth and 25% operating margins by 2030, fair value is estimated at $255 per share—well below current levels. Exceptional execution and regulatory wins support the business, but current valuation leaves little room for upside or error. Read the full article on Seeking AlphaActualización de narrativa • Aug 18
NTRA: Guideline MRD Tailwinds Will Drive Future Oncology Volume Upside
Natera's analyst price target has been raised from $330 to $375, with analysts pointing to stronger modeled revenue growth supported by continued execution in oncology and Women's Health, record and guideline supported Signatera volumes, and updated models after Q2 results that still factor in a higher discount rate and a higher future P/E multiple, alongside somewhat lower projected profit margins. Analyst Commentary Recent Street research around Natera centers on sustained execution in oncology and minimal residual disease, or MRD, testing, with Signatera frequently highlighted as a key driver.Actualización de narrativa • Aug 04
NTRA: Guideline And Regulatory MRD Tailwinds Will Drive Long-Term Upside Potential
The analyst price target for Natera has been raised by $20, from $310 to $330. Analysts cite larger addressable markets, ongoing volume trends, and a series of recent guideline wins and regulatory approvals that support slightly higher revenue growth, profit margins, and a higher future P/E in updated models.
Actualización de narrativa • Jul 20
NTRA: Guideline And Regulatory Tailwinds Will Support Balanced 2026 MRD Outlook
The updated analyst price target for Natera moves from $260.05 to $282.14, reflecting analysts' use of higher group multiples and ongoing expectations around large addressable markets, volume trends, and guideline and regulatory catalysts for Signatera in their revised models. Analyst Commentary Recent research on Natera shows a cluster of higher price targets and mostly positive ratings, with a few more cautious voices tempering expectations.Actualización de narrativa • Jul 06
NTRA: Guideline And Regulatory MRD Tailwinds Will Support Measured Long-Term Trajectory
Natera's updated fair value estimate edges up to $310, supported by analysts' higher price targets across the diagnostics sector and their view that trends in procedure volumes, capital spending, guideline support for Signatera, and MRD adoption continue to favor the company's testing portfolio. Analyst Commentary Recent research coverage on Natera has been active, with several bullish analysts revisiting their assumptions around the company’s testing portfolio, guideline traction for Signatera, and minimal residual disease, or MRD, adoption.Actualización de narrativa • Jun 22
NTRA: MRD Guideline Tailwinds Will Support 2026 Catalyst Heavy Outlook
The analyst price target for Natera has edged down slightly to $260.05 from about $260.89, as analysts factor in updated assumptions for revenue growth, profit margins, and future P/E. They also highlight the potential uptake of Signatera following new NCCN guideline support and a continued focus on minimal residual disease testing adoption and reimbursement.Artículo de análisis • Jun 20
Natera (NTRA) Stock Could Be 11.3% Undervalued After Prospera Transplant Data
Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines. See our latest analysis for Natera. The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder...Actualización de narrativa • Jun 05
NTRA: MRD Leadership And FDA Approval Will Support Long-Term Trajectory
Analysts have made a modest adjustment to their outlook on Natera, with the average price target moving slightly and recent commentary highlighting the company’s position in molecular residual disease testing. Firms have set a range of targets from $245 to $260 as they balance growth reinvestment with expectations for future operating leverage.Actualización de narrativa • May 22
NTRA: Molecular Residual Disease Leadership Will Support 2026 Catalyst Heavy Outlook
Natera's updated analyst price target has edged higher to about $261 from roughly $259, as analysts factor in a slightly higher fair value, a modestly adjusted discount rate and revenue growth outlook, and a stronger expected profit margin alongside a lower future P/E assumption. Analyst Commentary Recent Street research on Natera shows active recalibration of price targets, with several bullish revisions offset by a smaller number of trims.Artículo de análisis • May 13
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...Actualización de narrativa • May 05
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
Actualización de narrativa • Apr 20
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.Actualización de narrativa • Apr 05
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.Actualización de narrativa • Mar 22
NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.Actualización de narrativa • Mar 07
NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.Actualización de narrativa • Feb 21
NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.Actualización de narrativa • Feb 07
NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.Actualización de narrativa • Jan 24
NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.Actualización de narrativa • Jan 09
NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.Actualización de narrativa • Dec 26
NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.Actualización de narrativa • Dec 12
NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.Actualización de narrativa • Nov 27
NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.Actualización de narrativa • Nov 11
NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance
Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.Rentabilidad de los accionistas
| NTRA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 5.7% | 6.3% | -1.2% |
| 1Y | 104.4% | 47.2% | 18.3% |
Rentabilidad vs. Industria: NTRA superó a la industria US Biotechs, que obtuvo un rendimiento del 47.2% el año pasado.
Rentabilidad vs. Mercado: NTRA superó al mercado US, que obtuvo un rendimiento del 18.3% el año pasado.
Volatilidad de los precios
| NTRA volatility | |
|---|---|
| NTRA Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: NTRA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NTRA (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 6,138 | Steve Chapman | www.natera.com |
Natera, Inc, empresa de diagnóstico, se dedica al desarrollo y comercialización de servicios de pruebas moleculares en todo el mundo. Ofrece Signatera, una prueba sanguínea personalizada de ctADN para la evaluación de la ERM, la monitorización de la recurrencia temprana y la evaluación de la respuesta al tratamiento en pacientes con diagnóstico previo de cáncer; Latitude, una prueba sanguínea de ERM para el cáncer colorrectal; Altera, una prueba de perfil genómico integral basada en tejidos; y Empower, una prueba de cribado del cáncer hereditario. La empresa también ofrece Panorama, una prueba prenatal no invasiva; Horizon, una prueba de detección de portadores; Fetal Focus, una NIPT de un solo gen, o sgNIPT, que detecta 21 afecciones hereditarias de un solo gen; y Vistara, una NIPT de un solo gen, que detecta 25 afecciones de un solo gen.
Resumen de fundamentos de Natera, Inc.
| Estadísticas fundamentales de NTRA | |
|---|---|
| Capitalización bursátil | US$47.86b |
| Beneficios(TTM) | -US$192.35m |
| Ingresos (TTM) | US$2.71b |
17.7x
Ratio precio-ventas (PS)-248.8x
Ratio precio-beneficio (PE)¿Está NTRA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NTRA | |
|---|---|
| Ingresos | US$2.71b |
| Coste de los ingresos | US$941.25m |
| Beneficio bruto | US$1.77b |
| Otros gastos | US$1.96b |
| Beneficios | -US$192.35m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.33 |
| Margen bruto | 65.23% |
| Margen de beneficio neto | -7.11% |
| Ratio deuda/patrimonio | 4.4% |
¿Cómo se ha desempeñado NTRA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/24 21:02 |
| Precio de las acciones al final del día | 2026/08/21 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Natera, Inc. está cubierta por 36 analistas. 21 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Luke Sergott | Barclays |